000 01411 a2200385 4500
005 20250518002231.0
264 0 _c20200324
008 202003s 0 0 eng d
022 _a1549-490X
024 7 _a10.1634/theoncologist.2018-0452
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aDel Rivero, Jaydira
245 0 0 _aPhase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.
_h[electronic resource]
260 _bThe oncologist
_c01 2019
300 _a16-e14 p.
_bdigital
500 _aPublication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAntineoplastic Agents
_xpharmacology
650 0 4 _aBortezomib
_xpharmacology
650 0 4 _aCarcinoma, Neuroendocrine
_xdiet therapy
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aPiperidines
_xpharmacology
650 0 4 _aProto-Oncogene Mas
650 0 4 _aQuinazolines
_xpharmacology
650 0 4 _aThyroid Neoplasms
_xdiet therapy
700 1 _aEdgerly, Maureen
700 1 _aWard, Jean
700 1 _aMadan, Ravi A
700 1 _aBalasubramaniam, Sanjeeve
700 1 _aFojo, Tito
700 1 _aGramza, Ann W
773 0 _tThe oncologist
_gvol. 24
_gno. 1
_gp. 16-e14
856 4 0 _uhttps://doi.org/10.1634/theoncologist.2018-0452
_zAvailable from publisher's website
999 _c28915860
_d28915860